Volume 29, Number 6—June 2023
Dispatch
SARS-CoV-2 Seroprevalence and Cross-Variant Antibody Neutralization in Cats, United Kingdom
Figure 2
![Dominant variant of seropositive samples by date in study of SARS-CoV-2 seroprevalence and immunity in cats, United Kingdom, April 2020–February 2022. A) Timeline of key events during the COVID-19 pandemic in the United Kingdom, including the emergence of major variants into the human population. B) Seropositive samples from cats, categorized by dominant variant and plotted by month. B.1 indicates ancestral/wild-type virus.](/eid/images/22-1755-F2.jpg)
Figure 2. Dominant variant of seropositive samples by date in study of SARS-CoV-2 seroprevalence and immunity in cats, United Kingdom, April 2020–February 2022. A) Timeline of key events during the COVID-19 pandemic in the United Kingdom, including the emergence of major variants into the human population. B) Seropositive samples from cats, categorized by dominant variant and plotted by month. B.1 indicates ancestral/wild-type virus.
Page created: April 13, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.